在西班牙，克拉屈滨片和富马酸二甲酯治疗复发缓解型多发性硬化症的成本效益分析。
Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
机构信息
Hospital Clínico San Carlos, Neurology Department, C/ Prof Martín Lagos, 28040 Madrid, Spain.
HEALTH VALUE, HE Department, C/ Virgen de Aránzazu, 21, 28034 Madrid, Spain.
出版信息
J Comp Eff Res. 2023 Feb;12(2):e220193. doi: 10.2217/cer-2022-0193. Epub 2023 Jan 27.
To analyze the cost-effectiveness of treatment of relapsing remitting multiple sclerosis (RRMS) with cladribine tablets (CladT) and dimethyl fumarate (DMF) from the perspective of the Spanish National Health System (NHS). A probabilistic Markov model (second-order Monte Carlo simulation) with a 10-year time horizon and annual Markov cycles was performed. CladT was the dominant treatment, with lower costs (-74,741 € [95% CI: -67,247; -85,661 €]) and greater effectiveness (0.1920 [95% CI: -0.1659; 0.2173] QALY) per patient, compared with DMF. CladT had a 95.1% probability of being cost-effective and a 94.1% chance of being dominant compared with DMF. CladT is the dominant treatment (lower costs, with more QALYs) compared with DMF in the treatment of RRMS in Spain.
从西班牙国家卫生系统（NHS）的角度分析氯法拉滨片（CladT）和富马酸二甲酯（DMF）治疗复发缓解型多发性硬化症（RRMS）的成本效益。采用具有 10 年时间范围和年度马尔可夫循环的概率马尔可夫模型（二阶蒙特卡罗模拟）进行分析。CladT 是一种具有优势的治疗方法，与 DMF 相比，其成本更低（-74741 欧元[95%置信区间：-67247 欧元至-85661 欧元]），效果更好（每个患者的 0.1920 [95%置信区间：-0.1659；0.2173] QALY）。与 DMF 相比，CladT 具有 95.1%的成本效益概率和 94.1%的优势概率。与 DMF 相比，CladT 是治疗西班牙 RRMS 的优势治疗方法（成本更低，QALY 更多）。
Zotero 插件